MTEP
 | |
| IUPAC ime | |
|---|---|
3-[(2-metil-1,3-tiazol-4-il)etinil]piridin | |
| Identifikatori | |
| CAS broj | 329205-68-7  |
| ATC kod | none |
| PubChem | CID 9794218 |
| Hemijski podaci | |
| Formula | C11H8N2S |
| Molarna masa | 200,260 g/mol |
| |
3-[(2-Metil-4-tiazolil)etinil]piridin (MTEP) je lek koji se koristi u naučnim istraživanjima. Razvila ga je kompanija Merck & Co.. On je selektivan alosteran antagonist metabotropnog glutamatnog receptora mGluR5. On je identifikovan putem studija odnosa strukture i aktivnosti starijeg mGluR5 antagonista MPEP.[1] MTEP je naknadno korišten kao vodeće jedinjenje za novije i potentnije lekiva.[2][3]
Reference
[уреди | уреди извор]- ^ Cosford ND; Tehrani L; Roppe J; et al. (2003). „3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity”. J. Med. Chem. 46 (2): 204—6. PMID 12519057. doi:10.1021/jm025570j.
- ^ Iso Y; Grajkowska E; Wroblewski JT; et al. (2006). „Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications”. J. Med. Chem. 49 (3): 1080—100. PMID 16451073. doi:10.1021/jm050570f.
- ^ Kulkarni SS, Newman AH (2007). „Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists”. Bioorg. Med. Chem. Lett. 17 (11): 2987—91. PMC 1973162
. PMID 17446071. doi:10.1016/j.bmcl.2007.03.066.
